Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: The objective was to determine whether Nilotinib crosses the blood brain barrier (BBB). Background: Parkinson's disease (PD) involves death of dopamine producing neurons in…Apomorphine treatment in advanced Parkinson’s disease (PD): Duration of treatment and safety experience in a managed care program in Germany
Objective: To evaluate the duration of treatment (DOT) and safety of apomorphine continuous subcutaneous infusion (CSI) in patients with advanced PD inscribed in a managed…Establishment of InMotion, an independent, fee-free community center for persons with movement disorders
Objective: To describe the establishment of a community center, InMotion (IM), for persons with movement disorders. Background: Needs of people with movement disorders grow with…When is the worst period of nocturnal hypokinesia in Parkinson’s disease? A sensor-based analysis
Objective: To quantify the number of turning in bed throughout the night as a determinant of the severity of nocturnal hypokinesia. Background: Nocturnal hypokinesia or…Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations
Objective: To assess how the efficacy of tozadenant differed by region in a randomized, double-blind, placebo-controlled trial of Parkinson's disease patients with motor fluctuations. Background:…Distribution of oscillatory activities in MRI confirmed subthalamic nucleus subregions
Objective: To explore the differences and similarities of oscillatory activity between subregions of the subthalamic nucleus (STN). Background: In Parkinson's disease (PD), treatment driven changes…Minimal impact of “interleaving” on neuromodulation device battery drain when interleave frequency is halved
Objective: To contrast neurostimulator battery decay subsequent to the implementation of interleaving with that prior to interleaving. Background: Neurostimulators permit “interleaving”, which allows different same-lead…Improving parkinsonism in DBS poor-responders by surgical lead revision of subthalamic electrodes
Objective: If subthalamic deep brain stimulation (STN-DBS) results in poor symptom control or adverse side effects at low stimulation threshold surgical lead revision for optimal…A case of thalamic malignant glioma formation in a patient with STN-DBS for Parkinson’s disease
Objective: We present a case of development of malignant glioma (glioblastoma multiforme) in the area adjacent to electrostimulation zone in a patient with chronic STN-DBS,…The score changes of clinical symptom assessment scales for multiple system atrophy in 2-3 years
Objective: To examine the extent of disease progression for multiple system atrophy (MSA) during relatively long duration. Background: The knowledge of MSA natural history is…
- « Previous Page
- 1
- …
- 365
- 366
- 367
- 368
- 369
- …
- 388
- Next Page »